Prognostic factors after potentially curative resection in stage II or III colon cancer

Kurume Medical Journal

Volumn 52, Issue 3, 2005, Pages 67-71

  Ogata, Yutaka ^a   Torigoe, Shojiro ^a   Matono, Keiko ^a   Sasatomi, Teruo ^a   Ishibashi, Nobuya ^a   Shida, Seiichiro ^a   Ohkita, Akira ^a   Mizobe, Tomoaki ^a   Ikeda, Satoru ^a   Ogou, Shujiro ^a   Ozasa, Hiroyuki ^a   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colon cancer; Metastasis to the mesenteric lymph node; Oral fluoropyrimidine; Postoperative adjuvant chemotherapy; Prognostic factor

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MESENTERY LYMPH NODE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 32844454337     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.52.67     Document Type: Article

References (18)

1. Greenlee RT, Murray T, Bolden S, and Wingo PA. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
2. International Multicentric Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-944.
3. International Multicentric Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17:1356-1363.
4. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002; 38:1429-1436.
5. Sakamoto J, Hamada C, Kodaira S, Nakazato H, and Ohashi Y. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 1999; 29:78-86.
6. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484-492.
7. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors, 6th edn, Edited by Sobin LH, Wittekind Ch WILEY-liss, New York, 2002.
8. Shirouzu K, Isomoto H, Morodomi T, and Kakegawa T. Carcinomatous lymphatic permeation: prognostic significance in patients with rectal carcinoma a long term prospective study. Cancer 1995; 75:4-10.
9. Shirouzu K, Isomoto H, Kakegawa T, and Morimatsu M. (1991) A prospective clinicopathologic study of venous invasion in colorectal cancer. Am J Surg 1991; 162:216-222.
10. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11:909-913.
11. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16:2739-2744.
12. Saltz LB, Cox JV, Blanke C, Rosen LS, Rosen LS et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
13. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
14. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735-1743.
15. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553-3559.
16. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-250.
17. Park YJ, Park KJ, Park JG, Lee KU, Choe KJ et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutive operated cases. World J Surg 1999; 23:721-726.
18. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.